Which Is a Better Investment, AstraZeneca PLC or Zoetis Inc. Stock?
Learn more about whether AstraZeneca PLC or Zoetis Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Tudor Pop
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.
Commentary & Analysis
Why Zoetis Inc.’s (ZTS) Stock Is Up 5.45%
As of Thursday, August 06, Zoetis Inc.’s ZTS share price has surged by 5.45%, which has investors questioning if this is right time to sell.Jenna Brashear
What You Need to Know About Zoetis Inc.'s Q3 Earnings
Zoetis Inc.'s fiscal Q3 earnings report was released on Thursday, August 06. Let's dive in to see if (ZTS) missed or beat analyst's expectations.Michael Rose
Is Zoetis Inc. (ZTS) Overvalued?
We dive into why Zoetis Inc. (ZTS) could be considered overvalued on 2026-07-17, based on AAII’s Value Score and Grade.Michael Rose
Which Is a Better Investment, Pfizer Inc. or Zoetis Inc. Stock?
Learn more about whether Pfizer Inc. or Zoetis Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Michael Rose
Financial Summary
| Share Statistics | ZTS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $33,483.5 | $464.0 | 91% |
|
| Shares Out (Mil) | 417.7 | 42.7 | 86% |
|
| Institutional Ownership | 99.9% | 82.2% | 96% |
|
| Float (Mil) | 412.4 | 44.3 | 83% |
|
| Beta | 0.73 | 0.73 | 43% |
|
| Avg Daily Volume (000s) | 3,931 | 292 | 90% |
|
| Price Change (52-week) |
(44.9%) | 55.0% | 22% |
|
| Growth | ZTS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 7.2% | 6.1% | 47% |
|
| Net Income (5yr) | 10.3% | (2.4%) | 56% |
|
| EPS (5yr) | 12.0% | 14.9% | 51 |
|
| Dividends (5yr) | 20.1% | 0.0% | 90% |
|
| Cash Flow (5yr) | (27.0%) | (15.1%) | 23% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 13 | 14 | 15 | |
| Current EPS | $1.507 | $6.215 | $6.448 | |
| Month Ago EPS | $1.508 | $6.206 | $6.531 | |
| # Rev Up | 0 | 1 | 0 | |
| # Rev Down | 0 | 0 | 1 | |
| Three Months Ago EPS | $1.844 | $6.873 | $7.390 | |
| Year/Year Chg | (8.7%) | 3.2% | 15.1% | |
| Financials | ZTS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $9,525 | $416 | 83% |
|
| Net Income (TTM) (Mil) | $2,637 | ($11) | 93% |
|
| EPS (TTM) | $6.129 | ($0.700) | 89% |
|
| Operating Cash Flow (TTM) (Mil) | $2,840 | ($7) | 91% |
|
| Net Cash Flow (TTM) (Mil) | ($97) | $5 | 15% |
|
| Long-Term Debt (Q1) (Mil) | $9,255 | $6 | 91% |
|
| Enterprise Value (Q1) (Mil) | $36,629 | $493 | 90% |
|
| Valuation | ZTS | Industry Median |
Percentile (All Stocks) |
|
| P/B | 10.66 | 2.09 | 92% |
|
| P/E | 13.2 | 17.3 | 32% |
|
| Dividend Yield | 2.6% | 0.0% | 81% |
|
| PEG (5yr hist) | 1.1 | 1.2 | 50% |
|
| Ratios | ZTS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 71.7% | 69.4% | 82% |
|
| Net Margin | 27.7% | 3.2% | 86% |
|
| ROA | 17.8% | (22.2%) | 95% |
|
| ROE | 64.9% | (21.0%) | 94% |
|
| Liabilities to Assets | 79.1% | 32.3% | 74% |
|
| F-Score | 6 | 3 | 67% |
|
Passing Stock Screens
As of 10/23/2026, from a list of 60 stock screening strategies,
GURU STRATEGY
Neff Screen
Factors: Value, Growth
An approach using a stringent contrarian viewpoint—finding undervalued, out-of-favor stocks in the bargain basement that have an optimistic future.
| Performance Since Inception: | 14.4% |
| +/- S&P 500: | +6.9 |
